Table 1 Eag1 expression and clinicopathological characteristics.
From: Ether à go-go potassium channel expression in soft tissue sarcoma patients
Number of Tumours (%) | Eag1 expression (%) | |
|---|---|---|
Sex | ||
Male | 54 (45%) | 35 (65%) |
Female | 67 (55%) | 51 (76%) |
Age (years) | ||
< 14 | 11 (9%) | 9 (82%) |
15 – 34 | 19 (16%) | 14 (74%) |
35 – 64 | 65 (54%) | 46 (71%) |
> 65 | 26 (21%) | 17 (65%) |
Histology | ||
Fibrosarcoma | 12 (10%) | 8 (67%) |
Leiomyosarcoma | 26 (22%) | 19 (73%) |
Liposarcoma | 32 (26%) | 18 (56%) |
Malignant fibrous histiocytoma | 22 (18%) | 18 (81%) |
Rhabdomyosarcoma | 17 (14%) | 14 (82%) |
Synovial sarcoma | 12 (10%) | 9 (75%) |
Grade | ||
Low | 70 (58%) | 49 (70%) |
Moderate | 23 (19%) | 15 (65%) |
High | 28 (23%) | 21 (75%) |
Size | ||
< 5 cm | 74 (61%) | 52 (70%) |
> 5 cm | 47 (39%) | 33 (70%) |
Site | ||
Primary | 76 (63%) | 57 (75%) |
Recurrence | 32 (26%) | 18 (56%) |
Metastasis | 13 (11%) | 11 (85%) |
Total | 121 | 86 (71%) |